nSMase3: Novel neutral Sphingomyelinase and its use for diagnostics andtherapy with focus on heart muscle diseases and male fert
A novel human TNF-responsible neutral phingomyelinase enzyme (nSMase3) has been identified. Furthermore, the invention relates to the use of nSMase3 as pharmaceutical and diagnostic target
and to appropriate test systems. The human enzyme was identified by screening database sequences with up to now unknow n function w ith a short sequence derived from a bovine neutral sphingomyelinase. The identified nSMase3 shows no significant homologies to the well-know n human neutral sphingomyelinases type 1 and type 2.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Retinoblastoma: Eye-Catching Investigation into Retinal Tumor Cells
A research team from the Medical Faculty of the University of Duisburg-Essen and the University Hospital Essen has developed a new cell culture model that can be used to better…
A Job Well Done: How Hiroshima’s Groundwater Strategy Helped Manage Floods
Groundwater and multilevel cooperation in recovery efforts mitigated water crisis after flooding. Converting Disasters into Opportunities Society is often vulnerable to disasters, but how humans manage during and after can…
Shaping the Future: DNA Nanorobots That Can Modify Synthetic Cells
Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of “DNA origami”. The system they developed may facilitate the…